Rare Disease Research UK
Rare Disease Research UK is a publicly funded national research platform launched in July 2023 that coordinates 11 specialized research nodes across UK universities to accelerate rare disease science, serving academic researchers, NHS clinicians, patient organizations, and industry partners under a £14 million MRC/NIHR grant.
- Company typePrivate
- Founded2023
- HeadquartersNewcastle upon Tyne, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Rare Disease Research UK does
Rare Disease Research UK (RD-TRC) is a UK-wide research platform launched in July 2023 to coordinate and accelerate research into rare diseases. The platform is built around a central coordinating Hub at Newcastle University and a network of 11 specialized research nodes distributed across leading UK universities, each focused on distinct capabilities such as cell and gene therapy, genomic medicine, bioinformatics, lipidomics, metabolomics, and nucleic acid therapeutics. The platform serves academic researchers, NHS clinical teams, patient communities, and industry partners seeking to translate rare disease science into therapies, with Genetic Alliance UK embedded as a partner to coordinate the involvement of more than 70 patient organizations across the country.
The platform's underlying technical components include multi-omic analytical pipelines, genomic variant interpretation frameworks, polygenic risk scoring, and LC-MS/MS lipidomic methods, all of which draw on access to NHS clinical data, Genomics England sequencing infrastructure, and national biobanks. The November 2025 UK Regulatory and Access Frameworks workshop, the annual conference series, and the January 2026 Involvement by Design Report formalize the platform's role as a convening and translational authority linking scientific research, patient involvement, and regulatory pathways.
Rare Disease Research UK's business model is non-commercial: it is funded by a £14 million joint grant from the Medical Research Council and NIHR over five years, with no disclosed product pricing, licensing revenue, or customer contracts. Its "customers" in the functional sense are researchers and patient cohorts served through the nodes, while its funding base is concentrated in two UK government research bodies. Industry engagement occurs through translational partnerships such as the LifeArc collaboration on the RareMap project, but these are research collaborations rather than commercial revenue streams.
Rare Disease Research UK firmographics
Firmographics- Name
- Rare Disease Research UK
- Legal name
- Rare Disease Research UK
- Website
- https://rd-research.org.uk
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Rare Disease Research UK is a publicly funded national research platform launched in July 2023 that coordinates 11 specialized research nodes across UK universities to accelerate rare disease science, serving academic researchers, NHS clinicians, patient organizations, and industry partners under a £14 million MRC/NIHR grant.
- Ownership category
- akta.pro rank
Rare Disease Research UK industry classification
Industry- Product category
- Rare Disease Research Platform
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Rare Disease & Special Needs Support Organizations (BPAGACAM)
Keywords
Where Rare Disease Research UK is headquartered
LocationHeadquarters
- HQ city
- Newcastle upon Tyne
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Rare Disease Research UK business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Government Research Funding: The platform was established with £14 million investment over five years from the Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) for rare disease research coordination and projects
Distribution channels4 records
Marketing channels7 records
Rare Disease Research UK product offering
Product offeringCore offering
Rare Disease Research UK operates a UK-wide research coordination platform consisting of a central Hub led by Newcastle University and eleven specialist research nodes based at universities across the United Kingdom. The platform coordinates academic, clinical, industry and patient communities to accelerate diagnosis, treatment and understanding of rare diseases affecting approximately 3.5 million people in the UK. It supports activities including national genetic variant databases, lipidomics/metabolomics diagnostics, nucleic acid therapy development, biobanking, clinical trial design and patient and public involvement and engagement (PPIE).
Product overview
Rare Disease Research UK is a UK-wide research platform launched in July 2023 following a £14 million investment from MRC and NIHR. The platform consists of a central coordinating Hub led by Newcastle University (partnered with Newcastle NHS Trust and Genetic Alliance UK) and eleven specialist research Nodes based at universities across the UK. The Nodes include: Cardiovascular, CAPTIVATE, ExPRESS, EpiGenRare, ELSI, HistioNode, Lipidomics and Metabolomics, mTOR Pathway Diseases, REOLUT, CILIAREN, and UPNAT. Additional services include Patient and Public Involvement and Engagement (PPIE) support, the RareMap landscape discovery tool, and annual conferences. The platform aims to improve diagnosis and treatment of rare diseases through better understanding by bringing together academic, clinical, industry researchers, patients, and charities.
Differentiator
Problem solved
Functional benefit
Products and services
- Rare Disease Research UK Platform (Hub) UK-wide research coordination platform consisting of a central coordinating Hub led by Newcastle University in partnership with The Newcastle upon Tyne Hospitals NHS Foundation Trust and Genetic Alliance UK. Provides cohesion and support to eleven specialist research nodes and serves researchers, NHS clinicians, industry partners, patient organisations and policymakers working on rare disease diagnosis and treatment.
- Cardiovascular Initiative Node Research node tackling fundamental challenges in understanding rare inherited cardiovascular conditions (ICCs), building a national variant database by linking all genetic testing laboratories across England in partnership with the NHS Genomic Medicine Service, Genomics England, the British Heart Foundation Data Science Centre and Cardiomyopathy UK. At least 1 in 200 people are affected by rare cardiovascular conditions.
- CAPTIVATE Node Research node bringing together UK leading trial experts to develop better ways to test new medicines for rare diseases in clinical trials, including 'one-stop-study' designs and Bayesian statistical methods to address the challenge of small patient populations.
- ExPRESS Node Early Assessment, Diagnosis and Treatment of Parkinsonism and Related Syndromes study focusing on Parkinson's disease, PSP, CBS and MSA. Aims to recruit at least 500 patients between 2023 and 2028 to build a biobank of blood samples and genetic data to improve early diagnosis accuracy and prognosis. Partners include PSP Association and MSA Trust.
- EpiGenRare Node Research node coordinating epigenomics of rare disorders, developing multi-omic approaches combining genomic and epigenomic data for accurate diagnosis, biomarker identification and identification of groups of diseases with common epigenetic mechanisms for therapeutic targeting. Co-led at University of Exeter and University of Manchester.
- ELSI Node Research node addressing ethical, legal and social implications of genetic testing and rare conditions research, focusing on consent, access to genomic testing, and the psychosocial impact of living with rare conditions. Led from the University of Manchester.
- HistioNode Research node tackling pressing problems caused by histiocytic disorders including HLH and histiocytic neoplasms, through networking, biobanking and collaboration with the National Disease Registration Service (NDRS). Patient involvement partner is Histio UK.
- Lipidomics and Metabolomics Node Research node bringing together mass spectrometrists, clinical scientists and patient groups to establish new routes for clinical access to metabolomic tests for rare disease diagnosis, translating LC-MS/MS methods for NHS metabolic laboratories and integrating lipidomics and metabolomics with genomics for diagnosis of syndromes without a name.
- mTOR Pathway Diseases Node Research node uniting rare mTOR pathway diseases as a single group including TSC, PROS and Smith-Kingsmore syndrome to improve diagnosis, treatment and clinical outcomes through united clinical and research efforts. Led from King's College London; the lead chairs the Platform Executive Board.
- REOLUT Node Research node creating a network of clinicians and researchers across the UK for rare early onset lower urinary tract disorders, including new types of genetic analysis to find causes of severe inherited bladder problems and genomic approaches for diagnosis and therapy optimisation.
- CILIAREN Node Renal Ciliopathies National Network establishing harmonised clinical, imaging and genetic work-up for all renal ciliopathy patients in the UK to improve diagnosis and develop precision medicine approaches, including functional validation for patient diagnosis and risk stratification of kidney failure.
- UPNAT Node UK Platform of Nucleic Acid Therapy for rare disease treatment, creating a national network to facilitate development of antisense oligonucleotide and other nucleic acid therapies for rare genetic disorders. Brings together scientists, clinicians, geneticists, patient advocates, industry partners and regulatory bodies, including MHRA engagement to streamline regulatory approvals.
- Patient and Public Involvement and Engagement (PPIE) Service Cross-cutting service delivered in partnership with Genetic Alliance UK supporting Platform members in delivering patient involvement through sharing best practice, guidance, webinars and workshops. Includes webinars on Introduction to Co-Production and Introduction to PPIE and the publication of 'Involvement by design' (January 2026) on addressing structural and cultural barriers to PPIE in academic research.
- RareMap Project creating an accessible resource introducing major UK-based rare disease programmes and their typical roles, including an interactive online tool for exploring the rare disease-relevant organisational landscape, a written report and a directory of organisations. Developed in collaboration with LifeArc in 2025.
Quantifiable outcome
- 500+ patients to be recruited for ExPRESS Parkinsonism study between 2023-2028
- +2 more outcomes
Companies that use Rare Disease Research UK
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Rare Disease Research UK technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability12 records
Feature4 records
Rare Disease Research UK partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- LifeArccoreCollaboration on RareMap project to map UK rare disease research landscape and create interactive online resource
- Newcastle UniversitycoreLead institution for the central coordinating Hub of the Rare Disease Research UK Platform
- The Newcastle upon Tyne Hospitals NHS Foundation TrustcorePartner in the Hub leadership consortium alongside Newcastle University and Genetic Alliance UK
- Genetic Alliance UKcorePartner in the Hub leadership consortium providing patient advocacy expertise and PPIE coordination
- NHS Genomic Medicine ServicecorePartnership with Cardiovascular Node to build on NHS clinical genetic testing pathways for rare cardiovascular research
- Genomics EnglandcoreCollaboration to bring together genomic data for rare cardiovascular conditions research
- British Heart Foundation Data Science CentreminorPartner in Cardiovascular Node research for data linkage and analysis
- Cardiomyopathy UKminorPatient organisation partner for Cardiovascular Rare Disease Node providing patient perspectives and engagement
- PSP AssociationminorUK charity partner for ExPRESS node research on Parkinsonism and related syndromes
- MSA TrustminorUK charity partner for ExPRESS node research on multiple system atrophy
- Histio UKminorPatient involvement partner for HistioNode working on histiocytic disorders research
- MRC Centre for Neurodevelopmental Disorders (CNDDs)minorJoint symposium partner with mTOR Pathway Diseases Node for rare neurodevelopmental disorders research
- The Mary Lyon Centre at MRC HarwellminorJoint event host for Resources and Funding Opportunities in Rare Diseases workshop
- MRC National Mouse Genetics NetworkminorJoint event host for Resources and Funding Opportunities in Rare Diseases workshop
- National Disease Registration Services (NDRS)minorCollaboration with HistioNode to understand medical needs of patients with histiocytosis across UK regions
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Rare Disease Research UK competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Rare Disease Research UK social profiles
Digital presenceRare Disease Research UK financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rare Disease Research UK leadership team
Management profileNumber of profiles
Profiles16 records
Rare Disease Research UK subsidiaries and ownership
Company hierarchySubsidiaries12 records
Rare Disease Research UK funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rare Disease Research UK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rare Disease Research UK
What does Rare Disease Research UK do?
Rare Disease Research UK operates a UK-wide research coordination platform consisting of a central Hub led by Newcastle University and eleven specialist research nodes based at universities across the United Kingdom. The platform coordinates academic, clinical, industry and patient communities to accelerate diagnosis, treatment and understanding of rare diseases affecting approximately 3.5 million people in the UK. It supports activities including national genetic variant databases, lipidomics/metabolomics diagnostics, nucleic acid therapy development, biobanking, clinical trial design and patient and public involvement and engagement (PPIE).
Is Rare Disease Research UK a public or private company?
Rare Disease Research UK is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Rare Disease Research UK founded?
Rare Disease Research UK was founded in 2023. It employs 1 to 10 people.
Where is Rare Disease Research UK based?
Rare Disease Research UK is headquartered in Newcastle upon Tyne, United Kingdom, in the Europe region.
How does Rare Disease Research UK make money?
One revenue line is on record: government Research Funding.
Does Rare Disease Research UK have an API?
No public API is recorded for Rare Disease Research UK.
What industry is Rare Disease Research UK in?
Rare Disease Research UK's product category is Rare Disease Research Platform. Its primary akta.pro industry code is BPAGACAM, Rare Disease & Special Needs Support Organizations. Its NAICS code is 54171 and its SIC code is 8731.